| Literature DB >> 21464965 |
Jason T Evans1, Robert L Serafino Wani, Laura Anderson, Andrea L Gibson, E Grace Smith, Annette Wood, Babatunde Olowokure, Ibrahim Abubakar, Jonathan S Mann, Sarah Gardiner, Helen Jones, Pam Sonnenberg, Peter M Hawkey.
Abstract
BACKGROUND: We describe the identification of, and risk factors for, the single most prevalent Mycobacterium tuberculosis strain in the West Midlands region of the UK. METHODOLOGY/PRINCIPALEntities:
Mesh:
Year: 2011 PMID: 21464965 PMCID: PMC3064665 DOI: 10.1371/journal.pone.0017930
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Incidence and cumulative total of the number of patients with the Mercian strain between 2004 and 2008.
Figure 2Geographical mapping of cases with the Mercian strain in the West Midlands between 2004 and 2008.
Primary Care Trusts (PCTs) are regional NHS organizations in England that provide primary and community care. The city of Wolverhampton where the focused epidemiological investigation was undertaken is highlighted in yellow. The postcode map was produced under license by ©Crown Copyright and database right 2010. Ordnance Survey License 100016969/100022432.
Figure 3Results of RFLP analysis for isolates of the Mercian strain across the Midlands between 1995 and 2003.
Each horizontal lane is an example of an individual M. tuberculosis strain from each location and year. The molecular sizes of the digested DNA fragments of MT14323 are shown in kilobases. The 8th IS6110 fragment was identified in an isolate from Wolverhampton in 2003.
Univariate and multi-variate analysis of sociodemographic, clinical, and bacteriological data for patients with the Mercian strain (n = 124) and all other patients with strain typing data (n = 2,066) in the West Midlands between 2004 and 2008.
| No. patients | Unadjusted | Adjusted | ||||||
| Variable | Mercian(n = 124) | WT(n = 2,066) | Odds Ratio | 95% CI | P | Odds Ratio | 95% CI | p |
| Gender | ||||||||
| Male | 77 | 1,118 | 1.38 | 0.95–2.01 | 0.09 | 1.03 | 0.65–1.62 | 0.91 |
| Age group (years) | ||||||||
| 0–14 | 4 | 45 | 1.27 | 0.45–3.59 | 0.69 | 0.35 | 0.07–1.63 | 0.18 |
| 15–44 | 92 | 1310 | 1.00 | 1.00 | Reference | |||
| 45–64 | 23 | 379 | 0.86 | 0.54–1.38 | 0.543 | 0.77 | 0.42–1.41 | 0.40 |
| >65 | 5 | 330 | 0.22 | 0.09–0.53 | <0.01 | 0.25 | 0.09–0.67 | <0.01 |
| HPU location in the West Midlands | ||||||||
| East | 47 | 1,126 | 1.00 | 1.00 | Reference | |||
| North | 10 | 206 | 1.16 | 0.58–2.34 | 0.67 | |||
| West | 67 | 727 | 2.21 | 1.50–3.24 | <0.01 | |||
| Local Authority | ||||||||
| Wolverhampton | 51 | 169 | 7.83 | 5.30–11.58 | <0.01 | 9.29 | 5.69–15.19 | <0.01 |
| Place of birth | ||||||||
| UK-born | 100 | 546 | 18.03 | 10.22–31.81 | <0.01 | 9.03 | 4.56–17.87 | <0.01 |
| Ethnic group | ||||||||
| Black Caribbean | 32 | 70 | 14.84 | 8.55–25.77 | <0.01 | 5.68 | 2.96–10.91 | <0.01 |
| Black African | 1 | 362 | 0.09 | 0.01–0.68 | 0.02 | 0.19 | 0.02–1.51 | 0.12 |
| Indian Sub-Continent | 33 | 1,102 | 1.00 | 1.00 | Reference | |||
| Other | 6 | 105 | 1.57 | 0.60–4.10 | 0.36 | 1.11 | 0.37–3.37 | 0.85 |
| White | 49 | 366 | 4.47 | 2.79–7.15 | <0.01 | 1.75 | 0.95–3.22 | 0.07 |
| Site of disease | ||||||||
| Pulmonary sputum smear positive | 59 | 655 | 1.00 | 1.00 | Reference | |||
| Pulmonary sputum smear other | 47 | 711 | 0.73 | 0.49–1.09 | 0.13 | 1.06 | 0.64–1.74 | 0.83 |
| Extra pulmonary | 18 | 685 | 0.29 | 0.17–0.50 | <0.01 | 0.62 | 0.33–1.18 | 0.15 |
| Clinical history of TB | ||||||||
| Previous diagnosis of TB | 10 | 85 | 0.60 | 0.30–1.20 | 0.15 | |||
| Treatment | ||||||||
| Patient admitted as in-patient | 25 | 329 | 1.04 | 0.64–1.65 | 0.89 | |||
| Treatment outcome at 12 months | ||||||||
| Treatment completed | 71 | 1,157 | 1.00 | 1.00 | Reference | |||
| Died | 3 | 108 | 0.45 | 0.14–1.46 | 0.19 | |||
| Lost to follow up | 4 | 72 | 0.91 | 0.32–2.55 | 0.85 | |||
| Still on treatment | 2 | 32 | 1.02 | 0.24–4.34 | 0.98 | |||
| Treatment stopped | 1 | 6 | 2.72 | 0.32–22.87 | 0.36 | |||
| Transferred out | 0 | 18 | - | - | - | |||
| Not completed unknown | 2 | 21 | 1.55 | 0.36–6.75 | 0.56 | |||
| Unknown | 2 | 13 | 2.51 | 0.56–11.32 | 0.23 | |||
| Treatment outcome at 12 months | ||||||||
| Successful | 73 | 1,189 | 0.89 | 0.47–1.66 | 0.71 | |||
| Drug Sensitivity Testing | ||||||||
| Resistance to any 1st line drug | 5 | 93 | 0.89 | 0.35–2.22 | 0.79 | |||
| MDR | 1 | 15 | 1.10 | 0.14–8.43 | 0.92 | |||
*P-values were considered as statistically significant if ≤0.05. Significant unadjusted values were included in the multi-variate model.
The wild-type (WT) consisted of tuberculosis patients infected with M. tuberculosis strains other than the Mercian strain.
Epidemiological data obtained from a city-wide investigation of patients with and without the Mercian strain in Wolverhampton, UK between 2003 and 2006.
| Unadjusted | Adjusted | |||||||
| Variable | Mercian(n = 35) | WT(n = 47) | Odds Ratio | 95% CI | p | Odds Ratio | 95% CI | p |
| Patient gender | ||||||||
| Female | 18 | 20 | 1.42 | 0.54–3.77 | 0.43 | |||
| Age group (years) | ||||||||
| 0–14 | 1 | 1 | 1.15 | 0.01–92.99 | 1.00 | |||
| 15–44 | 27 | 31 | 1.00 | 1.00 | Reference | |||
| 45–64 | 4 | 10 | 0.46 | 0.10–1.85 | 0.22 | |||
| >65 | 3 | 5 | 0.69 | 0.10–3.95 | 0.72 | |||
| Ethnic group | ||||||||
| Indian Sub-Continent | 11 | 23 | 1.00 | 1.00 | Reference | |||
| Black African | 0 | 6 | - | - | - | |||
| Black Caribbean | 9 | 6 | 3.06 | 0.75–13.46 | 0.07 | |||
| Other | 1 | 5 | 0.44 | 0.01–4.71 | 0.65 | |||
| White | 14 | 7 | 4.06 | 1.15–15.77 | 0.01 | |||
| Country of birth | ||||||||
| UK-born | 32 | 12 | 29.42 | 7.32–177.18 | <0.01 | 9.68 | 2.00–46.78 | <0.01 |
| Epidemiological History | ||||||||
| Previous contact with TB case | 24 | 11 | 6.94 | 2.42–21.50 | <0.01 | 3.40 | 0.92–12.59 | 0.07 |
| Previous contact with Mercian strain | 13 | 0 | 15.65 | 4.76–51.48 | <0.01 | |||
| Previous history of TB | 9 | 3 | 4.97 | 1.11–31.13 | 0.01 | |||
| Clinical co-factors | ||||||||
| Malignancy | 1 | 0 | 10.41 | 0.20–547.59 | 0.43 | |||
| Diabetes | 2 | 7 | 0.35 | 0.03–2.01 | 0.29 | |||
| Social factors | ||||||||
| Excess alcohol use | 16 | 4 | 8.78 | 2.42–41.01 | <0.01 | 6.26 | 1.45–27.02 | 0.01 |
| Cigarette smoking | 6 | 3 | 2.99 | 0.58–19.96 | 0.12 | |||
| Cannabis use | 11 | 2 | 10.02 | 1.96–100.33 | <0.01 | |||
| Unemployed | 21 | 23 | 1.56 | 0.59–4.18 | 0.32 | |||
| Clinical presentation | ||||||||
| Cavitary disease | 22 | 12 | 4.83 | 1.74–14.24 | <0.01 | 1.57 | 0.40–6.17 | 0.52 |
| Pulmonary disease | 31 | 34 | 2.93 | 0.79–13.64 | 0.07 | |||
| Sputum specimen | 25 | 24 | 2.37 | 0.87–6.84 | 0.06 | |||
| Positive microscopy | 22 | 17 | 2.94 | 1.10–8.19 | 0.02 | |||
| Treatment | ||||||||
| Therapy non-adherence | 7 | 3 | 3.61 | 0.75–23.42 | 0.06 | |||
| Weight loss after initiation of treatment | 8 | 0 | 12.99 | 3.00–56.28 | <0.01 | |||
| Completed treatment within 12 months | 26 | 36 | 0.64 | 0.17–2.29 | 0.43 | |||
| Drug Sensitivity Testing | ||||||||
| Resistance to any 1st line drug | 0 | 1 | - | - | - | |||
| MDR | 0 | 0 | - | - | - | |||
*P-values were considered as statistically significant if ≤0.05.
**OR for excess alcohol use and cannabis use combined.